EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation

Adi Jabarin iD, Guy Shtar iD, Valeria Feinshtein, Eyal Mazuz iD, Bracha Shapira, Lior Rokach, Shimon Ben-Shabat

Briefings in Bioinformatics · 03.07.2026 · 27 (4)

DOI: 10.1093/bib/bbag353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 08.07.2026. Verfasst von Adi Jabarin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Agents, Deep Learning, Tetracyclines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Innovation Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options. In this study, we introduce a target-based deep learning framework to investigate the anticancer activity of eravacycline (Erav), a United States Food and Drug Administration (FDA)-approved antibacterial agent previously identified in our work as a potential anticancer candidate through computational screening. We developed a novel two-phase in silico yeast-based prediction model to explore potential mechanisms of action, followed by in vitro and in vivo experimental validation. DNA polymerase kappa (POLK) and mutant p53 emerged as the top-ranked candidate targets. In the studied mutant p53 PDAC model, Erav treatment significantly reduced mutant p53 protein levels and was associated with marked downregulation of POLK protein expression. POLK is a previously underexplored DNA polymerase that has been reported to be overexpressed in multiple cancer types. In a subcutaneous xenograft model, Erav treatment resulted in a 76% reduction in tumor volume. Our findings demonstrate an association between Erav treatment and reduced POLK protein expression in the studied mutant p53 PDAC model, supporting POLK as a prioritized candidate for further investigation and providing preliminary mechanistic insight into Erav activity. This integrative computational–experimental pipeline offers a robust strategy for accelerating drug repurposing in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic AgentsDeep LearningTetracyclinesCarcinoma, Pancreatic DuctalHumansAnimalsMiceCell Line, TumorTumor Suppressor Protein p53Xenograft Model Antitumor Assays

Stichwörter der Autor:innen

POLKeravacyclinemolecular-based deep learning modelp53pancreatic cancer

Substanzen

Antineoplastic AgentsTumor Suppressor Protein p53Tetracyclines

Autor:innen und Institutionen

  • Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel.
  • Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel.

ORCID-Profile: Adi Jabarin, Guy Shtar, Eyal Mazuz

Förderung

  • Israel Innovation Authority

Zitieren

APA

Jabarin, A., Shtar, G., Feinshtein, V., Mazuz, E., Shapira, B., Rokach, L., & Ben-Shabat, S. (2026). Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation. Briefings in Bioinformatics, 27(4). https://doi.org/10.1093/bib/bbag353

Vancouver

Jabarin A, Shtar G, Feinshtein V, Mazuz E, Shapira B, Rokach L, et al. Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation. Briefings in Bioinformatics. 2026;27(4). doi:10.1093/bib/bbag353

BibTeX
@article{Jabarin2026,
  author = {Jabarin, Adi and Shtar, Guy and Feinshtein, Valeria and Mazuz, Eyal and Shapira, Bracha and Rokach, Lior and Ben-Shabat, Shimon},
  title = {Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation},
  journal = {Briefings in Bioinformatics},
  year = {2026},
  volume = {27},
  number = {4},
  doi = {10.1093/bib/bbag353}
}
Kostenlos starten →